# A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct04302025/  
OnCo record `nct04302025` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Alectinib, Entrectinib, Vemurafenib in non-small-cell lung cancer and small-cell lung cancer, run by Genentech, Inc., now recruiting.

## Summary

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT04302025 by Genentech, Inc., with 99 participants planned, started 2020-11-06 and due to reach its primary completion in 2026-11-30. Interventions recorded: Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04302025
- Phase: 2
- Setting: NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer
- Sponsor: Genentech, Inc.
- Enrolled: 99

## Sources

- ClinicalTrials.gov NCT04302025: https://clinicaltrials.gov/study/NCT04302025

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Alectinib](https://onco.cc/drugs/alectinib/), [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Cobimetinib](https://onco.cc/drugs/cobimetinib/), [Entrectinib](https://onco.cc/drugs/entrectinib/), [Pralsetinib](https://onco.cc/drugs/pralsetinib/), [Vemurafenib](https://onco.cc/drugs/vemurafenib/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct04302025.json